“The TriOx test was evaluated on blood samples from patients with and without cancer who had been referred by their GP with symptoms that might be due to cancer, as well as on asymptomatic individuals without cancer. It demonstrated the ability to detect cancers (including early-stage cancers) and distinguish between people who had cancer and those that did not with 94.9% sensitivity and 88.8% specificity. This would ensure that patients without cancer are not subjected to unnecessary procedures, while those with cancer can receive treatment sooner.”
From University of Oxford.